Dr. Matthew Moyle

Matthew Moyle is a biopharma veteran with a solid record of building and leading high-performing teams in the quest to deliver breakthrough medicines to patients. Dr Moyle has held executive-level positions at Boehringer Ingelheim, Amgen, Theraclone and Tanox, among others, resulting in the delivery of more than 20 drug candidates that have advanced to clinical testing, with several in late-stage development and two approvals thus far. During his tenure in industry, Dr Moyle has also led research programs that resulted in high-impact publications in immunology and virology. Dr Moyle received his BSc and PhD degrees in Biochemistry from the University of Toronto and completed postdoctoral studies at Genentech. Currently, Dr Moyle is engaged in new company creation within the venture capital community.

Scroll to Top